MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED PHARMACOKINETIC PROPERTIES

摘要

The present invention provides VEGF antagonists with improved pharmacokinetic properties. According to certain embodiments, a fusion polypeptide capable of antagonizing VEGF activity is provided comprising a modified extracellular ligand binding domain of a VEGF receptor fused to a multimerizing component.

主权项

1. A chimeric polypeptide capable of antagonizing VEGF activity consisting of a modified extracellular ligand binding domain of a VEGF receptor fused to a multimerizing component,
wherein the modified extracellular ligand binding domain consists essentially of an immunoglobulin-like (Ig) domain of human Flt1 and an Ig domain of human Flk1, wherein the Ig domain of human Flt1 is Ig domain 2, and wherein the Ig domain of human Flk1 is Ig domain 3, wherein the chimeric polypeptide exhibits improved pharmacokinetic properties as compared to a chimeric polypeptide consisting of only Ig domains of Flt1.